- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin‐1 blockade treatment decreasing cardiovascular risk
Authors
Keywords
-
Journal
CLINICAL CARDIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-15
DOI
10.1002/clc.23246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction
- (2017) Nicole M. De Jesus et al. HEART RHYTHM
- Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease
- (2015) I Jialal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Study of the association of IL-1β and IL-1RA gene polymorphisms with occurrence and severity of Familial Mediterranean fever
- (2015) José-Noel Ibrahim et al. European Journal of Medical Genetics
- Inflammation and plaque vulnerability
- (2015) G. K. Hansson et al. JOURNAL OF INTERNAL MEDICINE
- Interleukin-1 function and role in rheumatic disease
- (2015) Georg Schett et al. Nature Reviews Rheumatology
- Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus
- (2014) Adele Noe et al. CLINICAL THERAPEUTICS
- Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target
- (2014) Enrica Golia et al. Current Atherosclerosis Reports
- Global Sodium Consumption and Death from Cardiovascular Causes
- (2014) Dariush Mozaffarian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoteichoic acid isolated from Lactobacillus plantarum suppresses LPS-mediated atherosclerotic plaque inflammation
- (2013) Joo Yun Kim et al. MOLECULES AND CELLS
- Neutrophils, IL-1β, and gout: is there a link?
- (2013) Ioannis Mitroulis et al. Seminars in Immunopathology
- Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse
- (2012) Stefano Toldo et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen
- (2012) Paul M Ridker et al. CIRCULATION
- Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
- (2012) A. Rissanen et al. DIABETES OBESITY & METABOLISM
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Nicolino Ruperto et al. NEW ENGLAND JOURNAL OF MEDICINE
- Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent Type in Patients With ST-Segment Elevation Myocardial Infarction Randomized to Bare Metal or Drug-Eluting Stenting During Primary Percutaneous Coronary Intervention
- (2011) Mikkel Malby Schoos et al. AMERICAN JOURNAL OF CARDIOLOGY
- Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
- (2011) N. Schlesinger et al. ANNALS OF THE RHEUMATIC DISEASES
- Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
- (2011) Isabelle Koné-Paut et al. ARTHRITIS RESEARCH & THERAPY
- C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention
- (2009) Louai Razzouk et al. AMERICAN HEART JOURNAL
- Anti-inflammatory strategies for homocysteine-related cardiovascular disease
- (2009) Chih-Pei Lin Frontiers in Bioscience-Landmark
- Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
- (2009) Helen J. Lachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started